2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2775

Cutaneous Vasculitis Associated with Severe Bacterial Infections. Study of 27 Patients from a Series of 766 Cutaneous Vasculitis
Abstract Number: 521

CXCL13 Serum Levels Is Associated with Lymphoma, High B Cells Markers and Diseases activity in Primary Sjögren ’s Syndrome Patients
Abstract Number: 1704

CXCL4 Promotes Fibrosis By Increasing Expression of Extracellular Matrix Modifying Factors and By Facilitating Epithelial/Endothelial Mesenchymal Transition
Abstract Number: 2465

Cyclic Phosphatidic Acid (cPA) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α
Abstract Number: 1640

Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 316

Cytokines in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Tipping the Balance Between Interleukin-18 and Interferon-Gamma
Abstract Number: 810

Damage Assessment in Takyasu Arteritis Using Takayasu Arteritis Damage Score (TADS)
Abstract Number: 25

DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair
Abstract Number: 341

Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis
Abstract Number: 43

Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009
Abstract Number: 2506

Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab
Abstract Number: 2207

Decreased Bone Mineral Density in Patients with Ehler-Danlos Syndrome
Abstract Number: 1327

Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis
Abstract Number: 2733

Decreased CXCR3+CCR4-CCR6+ CD4+ Effector Memory T Cells in Patients with Granulomatosis with Polyangiitis
Abstract Number: 670

Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].